Sign Out
INTAXEL is indicated for the treatment of the following: Ovarian Cancer: As first line therapy in combination with cisplatin for the treatment of advance carcinoma of the ovary.
Second line therapy for the treatment of advanced metastatic carcinoma of the ovary.
Breast Cancer: Adjuvant treatment of node positive breast cancer administered sequentially to standard combination therapy.
Second line therapy after failure of anthracycline combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy which have included an anthracycline.
Non-Small Cell Lung Cancer: Intaxel in combination with cisplatin is effective for NSCLC patients who are not candidates for potentially curative surgery and/or radiation therapy.
Kaposi's Sarcoma: Second-line treatment of AIDS-related Kaposi's Sarcoma.
